Janus Henderson Group PLC Acquires 467,988 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Janus Henderson Group PLC lifted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 62.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,217,815 shares of the company's stock after purchasing an additional 467,988 shares during the quarter. Janus Henderson Group PLC owned 4.09% of Disc Medicine worth $77,170,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of IRON. Sterling Capital Management LLC boosted its holdings in shares of Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after buying an additional 503 shares during the period. Tower Research Capital LLC TRC increased its holdings in Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after purchasing an additional 266 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Disc Medicine during the 4th quarter worth about $235,000. Fiduciary Trust Co bought a new position in shares of Disc Medicine in the 4th quarter valued at about $257,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Disc Medicine in the fourth quarter valued at about $285,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IRON has been the subject of a number of analyst reports. Cantor Fitzgerald raised their price target on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Morgan Stanley restated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a report on Friday, March 7th. Stifel Nicolaus increased their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, January 24th. Scotiabank boosted their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. Finally, BMO Capital Markets raised their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $98.80.

Disc Medicine Stock Performance

Shares of IRON traded up $1.00 during trading hours on Friday, reaching $48.09. The stock had a trading volume of 442,342 shares, compared to its average volume of 349,606. The stock has a market capitalization of $1.66 billion, a PE ratio of -12.08 and a beta of 0.77. Disc Medicine, Inc. has a 12 month low of $30.65 and a 12 month high of $68.73. The company's 50-day moving average is $46.21 and its two-hundred day moving average is $54.87.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). Equities analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Activity at Disc Medicine

In related news, insider Pamela Stephenson sold 3,137 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,217.46. Following the sale, the insider now directly owns 69,529 shares in the company, valued at $3,794,892.82. This represents a 4.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mona Ashiya sold 202,146 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the transaction, the director now owns 208,742 shares of the company's stock, valued at approximately $11,332,603.18. The trade was a 49.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold 356,290 shares of company stock worth $19,336,901 over the last three months. Company insiders own 4.24% of the company's stock.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.